Royalty Pharma Plc (RPRX)
61.33
+0.02
(+0.03%)
USD |
NASDAQ |
Aug 24, 16:00
61.32
-0.01
(-0.02%)
After-Hours: 20:00
Royalty Pharma Shareholders Equity (Quarterly) : 6.833B for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 6.833B |
| March 31, 2026 | 6.889B |
| December 31, 2025 | 6.477B |
| September 30, 2025 | 6.414B |
| June 30, 2025 | 6.348B |
| March 31, 2025 | 6.689B |
| December 31, 2024 | 6.947B |
| September 30, 2024 | 6.870B |
| June 30, 2024 | 6.476B |
| March 31, 2024 | 6.500B |
| December 31, 2023 | 6.526B |
| September 30, 2023 | 6.139B |
| June 30, 2023 | 6.282B |
| March 31, 2023 | 5.954B |
| Date | Value |
|---|---|
| December 31, 2022 | 5.628B |
| September 30, 2022 | 6.152B |
| June 30, 2022 | 6.027B |
| March 31, 2022 | 5.778B |
| December 31, 2021 | 5.777B |
| September 30, 2021 | 5.793B |
| June 30, 2021 | 5.734B |
| March 31, 2021 | 4.882B |
| December 31, 2020 | 4.819B |
| September 30, 2020 | 4.452B |
| June 30, 2020 | 4.157B |
| March 31, 2020 | 5.160B |
| December 31, 2019 | 6.106B |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| AstraZeneca PLC | 47.33B |
| Johnson & Johnson | 84.97B |
| Viatris, Inc. | 14.26B |
| ANI Pharmaceuticals, Inc. | 597.21M |
| Corcept Therapeutics, Inc. | 705.78M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 19.82B |
| Total Liabilities (Quarterly) | 10.03B |
| Debt to Equity Ratio | 1.312 |
| Current Ratio | 2.797 |
| Net Debt Paydown Yield | -1.08% |